"US transcatheter tricuspid valve repair market grows by over 50% since launch in Q2 2024" was originally created and ...

JenaValve announced today that it received the green light to begin a new randomized controlled trial for its Trilogy device.

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, showcased 2-year follow up data from the ALIGN-AR Trial at TCT 2024. Concurrently, the ...

Zoom in or out of the page as needed for optimal reading comfort. You can also use a pinch gesture to zoom on touch devices.

The global prosthetic heart valve market is projected to be valued at USD 13,234.9 million by 2023 and is expected to grow ...

The Global Transcatheter Cardiac Valve Replacement (THVR) Market, valued at USD 6.54 billion in 2023, is anticipated to grow significantly with a CAGR of 14.8% over the forecast period of 2024 to 2032 ...

The four heart valves – pulmonary and tricuspid on the right, and aortic and mitral on the left of the heart ... The main issues included valve stenosis – when a valve does not open fully, restricting ...

Fewer rehospitalizations and better functional and QoL outcomes point to TAVI as a good choice, but longer-term data are ...

TTVR also led to "near elimination" of the TR, as 99.1% of people had moderate or less TR (and 95.3% mild or less) at the ...

The prevalence of PH was 12.8% in those hospitalized in 2018 with left heart disease, a lower percentage than found in previous research.

Jenscare Scientific Co., Ltd. ('Jenscare' or the 'Company') (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR ...

The EVOLVED trial found that early aortic valve intervention in patients with asymptomatic severe aortic stenosis (AS) and ...